Bio-boards under fire
06 May, 2002 by Daniella GoldbergIn the last month, three of Australia's most experienced listed biotechs have endured roller coaster rides on the stock market, in the case of all three because of upheaval at the board level.
Award nominations open
06 May, 2002 by Iain ScottThe Ian Clunies Ross Memorial Foundation has called for nominations for its 2003 National Science and Technology Award.
Health dept suspends clinical director
02 May, 2002 by Daniella GoldbergDr Bruce Hall, the clinical director in medicine at Liverpool Hospital, has been suspended by the New South Wales Health Department.
Kwik fix to avert disaster
30 April, 2002 by Daniella GoldbergJust over a month ago, with his company on the verge of big new international deals, Peptech managing director Stephen Kwik agreed to leave the company so the board could replace him with a CEO with scientific background and commercial expertise.
Compumedics buys US company, eyes Nasdaq
29 April, 2002 by Tanya HollisDeveloper of sleep disorders devices Compumedics has completed its first acquisition with the $US4 million purchase of Texas-based neurological instruments business Neuroscan.
Universities face review
29 April, 2002 by Daniella GoldbergNon-productive research, inflated course offerings, and inefficient bureaucrats in the higher education sector are some of the issues to be addressed in the first of a series of reviews of higher education by the Federal government.
Forum series threatened by lack of speakers
29 April, 2002 by Tanya HollisThe success of a Victorian government gene technology and biotech forum series was under threat because of a dearth of willing expert speakers, according to the Department of Human Services (DHS).
Biotech in Queensland: beautiful one day, smart the next
29 April, 2002 by Pete YoungQueensland is cooking up a thriving biotech sector by successfully blending half a dozen hard-to-find ingredients.
UNSW calls in heavyweights over allegations
26 April, 2002 by Daniella GoldbergOngoing investigations into the alleged misconduct of a University of New South Wales scientist, Prof Bruce Hall, are to be directed by a selection panel comprised of eminent scientist Sir Gustav Nossal and UNSW chancellor Dr John Yu and vice-chancellor Prof John Niland.
Start grants stopped in Fed funding freeze
26 April, 2002 by Tanya HollisBiotechs banking on an AusIndustry Start grant will have to look elsewhere for research cash after the government body revealed it would indefinitely freeze new funding.
Kate Parker: From biotech to rocket science
26 April, 2002 by Daniella GoldbergKate Parker helped nurture Invest Australia through its initial growth spurt 18 months ago. Now with the Commonwealth government agency growing again, restructuring and on the brink of becoming independent, Parker is leaving.
Employees get a share in biotech
26 April, 2002 by Tanya HollisCash-strapped biotech startups are increasingly rewarding their staff with shares in the company.
Freehills lawyer new VP of global IP group
24 April, 2002 by Iain ScottAdam Liberman, a partner at law firm Freehills, has been appointed vice-president of the Licensing Executives Society International (LESI), a global intellectual property organisations.
Partnering: try before you buy
24 April, 2002 by Melissa TrudingerAustralian biotechnology companies need to think very carefully about who they partner with, according to Garry Redlich, managing director of Peplin Biotech.
Biotech's natural selectors
24 April, 2002 by Iain ScottOne of the spin-offs of Australia's burgeoning biotech sector is an increasingly competitive recruitment sector.
